



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)

Thorsteinn LOFTSSON et al.)

Group Art Unit: 1623

Application No.: 10/750,940)

Examiner:

Filed: January 5, 2004)

Confirmation No.: 2037

For: HIGH-ENERGY CYCLODEXTRIN)
COMPLEXES)

FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants are submitting herewith a Form PTO-1449 substitute (two sheets) listing documents for consideration by the Examiner.

All of the listed documents were previously made of record in prior Application Serial No. 09/250,185, filed February 16, 1999, upon which Applicants rely for the benefits provided in 35 U.S.C. § 120. In accordance with 37 C.F.R. § 1.98, further copies of these documents are not required to be filed herein.

This statement and accompanying Form PTO-1449 substitute are being submitted together with the Missing Parts and thus before the first Office Action on the merits. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

It is respectfully requested that this Information Disclosure Statement be acknowledged and that a copy of applicants Form PTO-1449 substitute (2 sheets) be returned to the undersigned with the next official communication.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date May 21, 2004

By: Mary Katherine Baumeister
Mary Katherine Baumeister
Registration No. 26,254

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

1

of

2

Complete if Known

Application Number	10/750,940
Filing Date	January 5, 2004
First Named Inventor	Thorsteinn LOFTSSON et al.
Examiner Name	
Attorney Docket Number	016914-039

MAY 21 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
	5,134,127	A	Stella et al.	07-28-1992
	5,324,718		Loftsson	06-28-1994
	5,376,645		Stella et al.	12-27-1994
	5,472,954		Loftsson	12-05-1995

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation	
					Yes	No
	94/02518		WO	02-03-1994		

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Oh et al, <i>International Journal of Pharmaceutics</i> , 73, pp. 23-31 (1991).
	Loftsson and Brewster, <i>Pharm. Technol. Eur.</i> , 9(5), 26-34 (May 1997).
	Loftsson and Brewster, <i>J. Pharm. Sci.</i> , 85(10), 1017-1025 (October 1996).
	Rajewski and Stella, <i>J. Pharm. Sci.</i> , 85 (11), 1142-1169 (November 1996).
	Irie and Uekama, <i>J. Pharm. Sci.</i> , 86(2), 147-162 (February 1997).
	Stella and Rajewski, <i>Pharm. Res.</i> , 14(5), 556-567 (1997).
	Loftsson, <i>Pharmazie</i> , 53, 733-740 (1998).
	Frömming and Szejtli, <i>Cyclodextrins in Pharmacy</i> , Kluwer Academic Publishers, Dordrecht, The Netherlands, pp. 105-107 (1994).
	Loftsson and Ólafsson, <i>Int. J. Dermatol.</i> , 37, 241-246 (1998).
	Loftsson and Stefánsson, <i>Drug. Dev. Ind. Pharm.</i> , 23 (5), 473-481 (1997).
	Loftsson, Másson and Stefánsson, "Cyclodextrins as Permeation Enhancers", <i>Proceedings of the 17th Pharmaceutical Technology Conference and Exhibition</i> , volume 2, Dublin, pp. 313-324 (24-26 March 1998).
	Schwartz, Rhodes and Cooper, <i>J. Pharm. Sci.</i> , 66, 994-997 (July 1977).
	Loftsson and Bodor, <i>Acta Pharm. Nord.</i> , 1, 185-194 (1989). (Issue No. 4).
	Loftsson and Sigurdardóttir, "Cyclodextrins as skin penetration enhancers", in J. Szejtli and Sente (eds.), <i>Proceedings of the Eighth International Symposium on Cyclodextrins</i> , Kluwer Academic Publishers, pp. 403-406 (1996).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Substitute for form 1449A/PTO & 1449B/PTO				Complete if Known	
FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/750,940
				Filing Date	January 5, 2004
				First Named Inventor	Thorsteinn LOFTSSON et al.
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	016914-039

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Roth, Eger and Troschütz, <i>Pharmaceutical Chemistry</i> , Volume 2: Drug Analysis, Ellis Horwood, pp. 308-309 (1991).
	Gerecke, <i>Br. J. Clin. Pharmac.</i> , 11S-16S (1983).
	<i>Pharmaceutical Chemistry, Volume 2: Drug Analysis</i> , ed. H.J. Roth et al., pp. 302-311; 496-513; 518-525; 546-547; 580-581; 590-591; 594-597; 659-673; published by Ellis Horwood, London (1988).
	<i>Chemical Stability of Pharmaceuticals, A Handbook for Pharmacists</i> , Second Edition, ed. Kenneth A. Connors et al, pp. 257-263; 675-684; 764-773; published by Wiley-Interscience; John Wiley & Sons, New York (1986).
	Stenlake, <i>Foundations of Molecular Pharmacology, Volume 1, Medicinal and Pharmaceutical Chemistry</i> , pp. 512-513, published by The Athlone Press, University of London (1979).
	Junquera et al, <i>J. Org. Chem.</i> , 63, pp. 4349-4358 (1998). (WWW publ.: 06/11/98).
	Li et al, <i>Journal of Pharmaceutical Sciences</i> , 87, No. 12, pp. 1535-1537 (December 1998).
	Krishnamoorthy et al., "Complexation of Weak Acids and Bases with Cyclodextrins: Effects of Substrate Ionization and the Estimation and Interpretation of Association Constants," <i>International J. of Pharmaceutical Advances</i> , 1 (3), 330-343 (Jan., 1996).
	Loftsson et al., "Effects of 2-Hydroxypropyl- β -cyclodextrin on the Aqueous Solubility of Drugs and Transdermal Delivery of 17- β -Estradiol," <i>Acta Pharm. Nord.</i> 1 (4), 185-194 (1989).
	Menard et al., "Studies on the Effect of pH, Temperature and ring Size on the Complexation of Phenytoin with Cyclodextrins," <i>Pharm. Acta Helv.</i> , 63 (11), 303-308 (1988).
	Loftsson et al., "The Influence of Water-Soluble Polymers and pH on Hydroxylpropyl- β -cyclodextrin Complexation of Drugs," <i>Drug Development and Industrial Pharmacy</i> , 22 (5), 404-405 (1996); see also HCAPlus abstract.
	Selva et al., "Study of the Salts of Organic Hydroxy Acids of the Terfenadine β -Cyclodextrin Complex in Solution of Mass Spectrometry," <i>Journal of Mass Spectrometry</i> , 30 (1), 219-220 (1995).
	Fenyvesi et al., "Enhancement of the Drug Solubilizing Capacity of Hydroxypropyl- β -cyclodextrin by Ternary Complex Formation," in <i>The 7th Cyclodextrin Symposium</i> , T. Osa (ed.), Business Center for Academic Societies Japan, Tokyo, Japan, 1994, pages 414-418.
	Vikmon et al., "Terfenadine/Cyclodextrin/Hydroxyacid Multicomponent Complexes," in <i>The 7th Cyclodextrin Symposium</i> , T. Osa (ed.), Business Center for Academic Societies Japan, Tokyo, Japan, 1994, pages 480-483.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.